Bayer Secures Early Participation in the Sixth China International Import Expo, Seizing the 'Golden Key' to Shared Growth

ShanghaiSeptember 16, 2022 /PR Newswire/ --As the Fifth China International Import Expo (CIIE) officially enters the countdown stage50At the preparatory sprint stage, Bayer, a global leader in the life sciences industry, signed an advance agreement today at the National Exhibition and Convention Center for the sixth China International Import Expo (CIIE). This marks that Bayer will be present at the "CIIE appointment" for the sixth consecutive year, demonstrating its strong confidence in seizing the "CIIE opportunity" and its firm commitment to the Chinese market.

Dr. Gao Yong (fourth from the right) represents Bayer in signing up for the sixth CIIE in advance

 "The CIIE is a 'golden key' for the world to share China's development opportunities. As China enters a critical period of a new development stage, the ever-improving CIIE continues to exert a strong magnetic force. While showcasing the 'China-driven momentum' in promoting global economic and trade development, it has further strengthened the determination of many foreign companies, including Bayer, to establish roots in China and serve the Chinese market."Dr. Yong Gao, Vice President of Public & Government Affairs and Sustainable Development at Bayer ChinaStated: "Next year, Bayer will continue to take the stage at the CIIE, further showcasing our innovative strengths in healthcare and agricultural technology. Relying on a global innovation network and closely aligning with local needs, Bayer will fully support a better future shared with China."

As a "regular" of the CIIE who has never been absent, Bayer has been...2018Since the year, Bayer has consecutively participated in four sessions of the CIIE, comprehensively showcasing its core strengths in the life sciences field to the public, industry, and government through a series of innovative products, interactive experiences, and industry exchange activities. The successive successful hosting of the CIIE has not only enhanced the public influence of the Bayer brand but also injected strong momentum into Bayer's development in China.

2022This year marks the fifth anniversary of the CIIE, and it is also the year when Bayer enters China.140A milestone moment of the year. "Bayer in China140"Year, Unleashing Infinite Vitality" as the theme, Bayer will present its three major divisions—Prescription Medicines, Consumer Health, and Crop Science—at the fifth China International Import Expo (CIIE) as scheduled. In addition to having its largest exhibition scale ever, Bayer Crop Science will also lead the way in the Crop Seed Industry Zone of the fifth CIIE, promoting the revitalization of the seed industry. Through a dual-exhibition approach, Bayer looks forward to delivering an even more impressive "report card" for its development in China at this year's CIIE. With concrete actions, Bayer aims to benefit Chinese patients, consumers, and growers, while contributing to national strategies such as "Healthy China" and "Rural Revitalization."

(End)

About Bayer

Bayer as a multinational enterprise，Core Competencies in Health and Agriculture within the Life Sciences Domain. The company is committed to helping people overcome significant challenges posed by global population growth and aging through its products and services, benefiting humanity and promoting the prosperity of the planet. Bayer is dedicated to advancing sustainability and positively impacting its business. At the same time, the group enhances profitability and creates value through technological innovation and business growth. Globally, the Bayer brand stands for trustworthiness, reliability, and quality. In2021In the fiscal year, the number of employees at Bayer was approximately100,000Name, Sales441Million euros. Research and development investment excluding special items is54Million euros. For more information, please seewww.bayer.com。

 Forward-Looking Statements

This press release includes forward-looking statements by the management of Bayer AG based on current assumptions and forecasts. Various known and unknown risks, uncertainties, and other factors could cause the company's actual operational results, financial condition, development, or performance to differ materially from the estimates provided in the above forward-looking statements. These factors are disclosed on Bayer's official website.http://www.bayer.com/The publicly available reports of Bayer. The company has no obligation to update these forward-looking statements or adapt them to future events or developments.